Medical oncology and stem cell services provider TalkMed Group 5G3 has reported earnings of $32.7 million for the FY2023 ended Dec 31, 2023, up 9.7% from its earnings of $29.8 million in FY2022.
For 2HFY2023, earnings increased 4% y-o-y to $18.5 million.
Earnings per share (EPS) increased to 2.42 cents in FY2023 from 2.30 cents a year ago on a fully diluted basis.
For the full-year period, revenue increased 9.4% y-o-y to $83.8 million mainly due to the increase in revenue of approximately $7.7 million from the company’s oncology services segment patient visits increased.
This was partially offset by the decrease in $0.5 million from TalkMed’s 60%-owned subsidiary, CellVec, for cellular and gene therapy related products and services.
As at end-December, cash and cash equivalents stood at $89.9 million.
The group has proposed a final dividend of 1.3 cents for FY2023. Including the interim dividend of 0.9 cents paid out on Aug 22, 2023, this brings total dividends to 2.2 cents for the full-year period.
The final dividend will be paid on May 10.
Shares in TalkMed closed unchanged at 36.5 cents on Feb 20.
